Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.45 |
| ▸ | PDE2A | O00408 | 6/20 | 0.45 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268954 | 0.86 | NNMT (0.43) | PDE10APDE2ANNMTCYP11B2KMT2A | |
| SCHEMBL11955048 | 0.82 | NNMT (0.46) | PDE10APDE2ANNMTKMT2AALDH1A1 | |
| SCHEMBL17708289 | 0.79 | HPGD (0.38) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL1862887 | 0.78 | XPO1 (0.45) | PDE10APDE2ACYP11B2KMT2AMEN1 | |
| SCHEMBL29984568 | 0.78 | XPO1 (0.45) | PDE10APDE2ACYP11B2KMT2AMEN1 | |
| SCHEMBL9278108 | 0.78 | CYP11B2 (0.41) | PDE10APDE2ANNMTCYP11B2KMT2A | |
| SCHEMBL25163406 | 0.76 | CYP11B2 (0.39) | PDE10APDE2ACYP11B2KMT2AMEN1 | |
| SCHEMBL31180151 | 0.74 | NNMT (0.40) | PDE10APDE2ANNMTKMT2ACYP1A2 | |
| SCHEMBL1857560 | 0.74 | CTSS (0.39) | PDE10APDE2ACYP11B2KMT2AMEN1 | |
| SCHEMBL13865687 | 0.74 | RAB9A (0.39) | CYP11B2KMT2AMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | PDE10A 124/4885PDE2A 263/4885NNMT 1853/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | PDE10A 571/4885PDE2A 523/4885NNMT 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.